A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

Inclusion Criteria:

• Male or female, aged 10 to below 18 years at screening visit

• Have type 2 diabetes, treated with diet and exercise and metformin and/or basalinsulin. Metformin and/or basal insulin dose must be stable for at least 90 daysprior to study screening.

• Have HbA1c >6.5% to ≤11% at screening

• Have body weight ≥50 kilogram (kg) 110 pounds and BMI of >85th percentile of thegeneral age and gender-matched population for that country or region.

Exclusion Criteria:

• Have Type 1 diabetes mellitus (T1DM), or positive GAD65 or IA2 antibodies

• After the T2DM diagnosis, have a history of diabetic ketoacidosis or hyperosmolarsyndrome

• Have had ≥1 episode of severe hypoglycemia and/or ≥1 episode of hypoglycemicunawareness within the last 6 months.

• Have family or personal history of medullary thyroid carcinoma (MTC) or multipleendocrine neoplasia syndrome type 2 (MEN2).

• Had chronic or acute pancreatitis any time prior to study entry

• Female participants who are pregnant or breast feeding or intending to becomepregnant.

• Using prescription or over the counter medications for weight loss within 90 days ofthe screening visit.